Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/20634
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYang, Yuqing-
dc.contributor.authorSwierczak, Agnieszka-
dc.contributor.authorIbahim, Mohammad-
dc.contributor.authorPaiva, Premila-
dc.contributor.authorCann, Leonie-
dc.contributor.authorStevenson, Andrew W-
dc.contributor.authorCrosbie, Jeffrey C-
dc.contributor.authorAnderson, Robin L-
dc.contributor.authorRogers, Peter A W-
dc.date2019-01-22-
dc.date.accessioned2019-04-15T05:39:51Z-
dc.date.available2019-04-15T05:39:51Z-
dc.date.issued2019-04-
dc.identifier.citationRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2019; 133: 93-99-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/20634-
dc.description.abstractSynchrotron microbeam radiation therapy (MRT) is a new, evolving form of radiotherapy that has potential for clinical application. Several studies have shown in preclinical models that synchrotron MRT achieves equivalent tumor control to conventional radiotherapy (CRT) but with significantly reduced normal tissue damage. To explore differences between these two modalities, we assessed the immune cell infiltrate into EMT6.5 mammary tumors after CRT and MRT. CRT induced marked increases in tumor-associated macrophages and neutrophils while there were no increases in these populations following MRT. In contrast, there were higher numbers of T cells in the MRT treated tumors. There were also increased levels of CCL2 by immunohistochemistry in tumors subjected to CRT, but not to MRT. Conversely, we found that MRT induced higher levels of pro-inflammatory genes in tumors than CRT. Our data are the first to demonstrate substantial differences in macrophage, neutrophil and T cell numbers in tumors following MRT versus CRT, providing support for the concept that MRT evokes a different immunomodulatory response in tumors compared to CRT.-
dc.language.isoeng-
dc.subjectConventional radiotherapy-
dc.subjectImmune infiltrate-
dc.subjectMammary tumors-
dc.subjectMyeloid cells-
dc.subjectSynchrotron microbeam radiotherapy-
dc.titleSynchrotron microbeam radiotherapy evokes a different early tumor immunomodulatory response to conventional radiotherapy in EMT6.5 mammary tumors.-
dc.typeJournal Article-
dc.identifier.journaltitleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Australiaen
dc.identifier.affiliationMRC Centre for Reproductive Health, Queen's Medical Research Institute, The University of Edinburgh, UK-
dc.identifier.affiliationDepartment of Obstetrics & Gynaecology, University of Melbourne, Royal Women's Hospital, Parkville, Australiaen
dc.identifier.affiliationThe Imaging and Medical Beamline, Australian Synchrotron, Clayton, Australiaen
dc.identifier.affiliationCSIRO Materials Science & Engineering, Clayton, Australiaen
dc.identifier.affiliationSchool of Science, RMIT University, Melbourne, Australiaen
dc.identifier.affiliationFaculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Selangor, Malaysiaen
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Australiaen
dc.identifier.doi10.1016/j.radonc.2019.01.006-
dc.identifier.orcid0000-0002-6841-7422-
dc.identifier.pubmedid30935588-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.